Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Instagram Outage Disrupts Thousands of U.S. Users 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
WALTHAM, Mass., Aug. 24, 2016 -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in four upcoming investor conferences. The four conferences are:
- The Wells Fargo Global Healthcare Conference at the Westin Boston Waterfront in Boston on Wednesday, September 7. Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, Ph.D., President and COO of TESARO, will participate in an analyst-led moderated Q&A from 3:30 to 4:00 PM ET and in meetings with investors.
- The 11th Annual Citi Biotech Day at the Mandarin Oriental Hotel in Boston on Thursday, September 8, 2016. Lonnie Moulder will participate in a panel titled “Developing Cancer Therapeutics in 2016” at 8:00 AM ET. Also, Lonnie Moulder and Mary Lynne Hedley, Ph.D. will host meetings with investors.
- The Baird 2016 Healthcare Conference at the New York Palace Hotel in New York City on Thursday, September 8. Tim Pearson, EVP and CFO of TESARO, is scheduled to participate in an analyst-led fireside chat from 12:15 to 12:45 PM ET, and in meetings with investors.
- The Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology at the Lotte New York Palace in New York City on September 29, 2016. Lonnie Moulder and Jeff Hanke, Ph.D., EVP and Chief Scientific Officer of TESARO, will participate in an analyst-led fireside chat from 1:00 to 1:30 PM ET, and in meetings with investors.
Live webcasts of the presentations at the Wells, Baird and Leerink conferences and the panel at the Citi conference will be available by visiting the Investors section of the TESARO website at www.tesarobio.com. Archived replays of these webcasts will be available on the Company’s website for 14 days following the conferences.
About TESARO
TESARO, Inc. is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients.
For additional information, please contact: Jennifer Davis 1.781.325.1116 [email protected]
